LIMK1 Inhibitors
1 drugsAbout LIMK1
LIMK1, or LIM Kinase 1, is a protein kinase that regulates cellular processes through phosphorylation. Aberrant kinase activity is often implicated in disease, making them attractive targets for therapeutic intervention.
LIMK1 is a therapeutic target in oncology, though there is currently no genetic evidence data available linking it to specific diseases. The rationale for targeting this kinase may stem from its role in cellular signaling pathways known to be dysregulated in cancer.
LIMK1 is targeted by one FDA-approved drug, TAFINLAR (Novartis), a small molecule with 4 indications in oncology. TAFINLAR was first approved in 2013.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Advanced Lymphoma with only 2 trials.
- phase1 represents biological uncertainty with 55% completion.
Top Drugs
Novartis is the only company with an approved drug targeting LIMK1.
The single-player competitive landscape suggests high barriers to entry or limited perceived market opportunity.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets LIMK1, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel therapeutic approaches like antibodies or PROTACs.
Clinical Trials 131 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 47 | 25 | 13 | 8 | 66% |
| Phase 2 | 60 | 21 | 16 | 23 | 57% |
| Phase 3 | 18 | 12 | 1 | 5 | 92% |
| Phase 4 | 6 | 1 | 1 | 3 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2013 - 2013)
TAFINLAR was first approved in 2013 and remains the only approved drug.
The stagnant approval timeline indicates potential target saturation or challenges in developing new LIMK1-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 84 clinical trials targeting LIMK1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities